Hospital Epidemics Tracker (HEpiTracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers.


Journal

JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345

Informations de publication

Date de publication:
21 09 2020
Historique:
received: 21 06 2020
accepted: 21 08 2020
revised: 29 07 2020
pubmed: 28 8 2020
medline: 3 10 2020
entrez: 27 8 2020
Statut: epublish

Résumé

Hospital workers have been the most frequently and severely affected professional group during the COVID-19 pandemic, and have a big impact on transmission. In this context, innovative tools are required to measure the symptoms compatible with COVID-19, the spread of infection, and testing capabilities within hospitals in real time. We aimed to develop and test an effective and user-friendly tool to identify and track symptoms compatible with COVID-19 in hospital workers. We developed and pilot tested Hospital Epidemics Tracker (HEpiTracker), a newly designed app to track the spread of COVID-19 among hospital workers. Hospital staff in 9 hospital centers across 5 Spanish regions (Andalusia, Balearics, Catalonia, Galicia, and Madrid) were invited to download the app on their phones and to register their daily body temperature, COVID-19-compatible symptoms, and general health score, as well as any polymerase chain reaction and serological test results. A total of 477 hospital staff participated in the study between April 8 and June 2, 2020. Of note, both health-related (n=329) and non-health-related (n=148) professionals participated in the study; over two-thirds of participants (68.8%) were health workers (43.4% physicians and 25.4% nurses), while the proportion of non-health-related workers by center ranged from 40% to 85%. Most participants were female (n=323, 67.5%), with a mean age of 45.4 years (SD 10.6). Regarding smoking habits, 13.0% and 34.2% of participants were current or former smokers, respectively. The daily reporting of symptoms was highly variable across participating hospitals; although we observed a decline in adherence after an initial participation peak in some hospitals, other sites were characterized by low participation rates throughout the study period. HEpiTracker is an already available tool to monitor COVID-19 and other infectious diseases in hospital workers. This tool has already been tested in real conditions. HEpiTracker is available in Spanish, Portuguese, and English. It has the potential to become a customized asset to be used in future COVID-19 pandemic waves and other environments. ClinicalTrials.gov NCT04326400; https://clinicaltrials.gov/ct2/show/NCT04326400.

Sections du résumé

BACKGROUND
Hospital workers have been the most frequently and severely affected professional group during the COVID-19 pandemic, and have a big impact on transmission. In this context, innovative tools are required to measure the symptoms compatible with COVID-19, the spread of infection, and testing capabilities within hospitals in real time.
OBJECTIVE
We aimed to develop and test an effective and user-friendly tool to identify and track symptoms compatible with COVID-19 in hospital workers.
METHODS
We developed and pilot tested Hospital Epidemics Tracker (HEpiTracker), a newly designed app to track the spread of COVID-19 among hospital workers. Hospital staff in 9 hospital centers across 5 Spanish regions (Andalusia, Balearics, Catalonia, Galicia, and Madrid) were invited to download the app on their phones and to register their daily body temperature, COVID-19-compatible symptoms, and general health score, as well as any polymerase chain reaction and serological test results.
RESULTS
A total of 477 hospital staff participated in the study between April 8 and June 2, 2020. Of note, both health-related (n=329) and non-health-related (n=148) professionals participated in the study; over two-thirds of participants (68.8%) were health workers (43.4% physicians and 25.4% nurses), while the proportion of non-health-related workers by center ranged from 40% to 85%. Most participants were female (n=323, 67.5%), with a mean age of 45.4 years (SD 10.6). Regarding smoking habits, 13.0% and 34.2% of participants were current or former smokers, respectively. The daily reporting of symptoms was highly variable across participating hospitals; although we observed a decline in adherence after an initial participation peak in some hospitals, other sites were characterized by low participation rates throughout the study period.
CONCLUSIONS
HEpiTracker is an already available tool to monitor COVID-19 and other infectious diseases in hospital workers. This tool has already been tested in real conditions. HEpiTracker is available in Spanish, Portuguese, and English. It has the potential to become a customized asset to be used in future COVID-19 pandemic waves and other environments.
TRIAL REGISTRATION
ClinicalTrials.gov NCT04326400; https://clinicaltrials.gov/ct2/show/NCT04326400.

Identifiants

pubmed: 32845852
pii: v6i3e21653
doi: 10.2196/21653
pmc: PMC7511223
doi:

Banques de données

ClinicalTrials.gov
['NCT04326400']

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e21653

Informations de copyright

©Joan B Soriano, Esteve Fernández, Álvaro de Astorza, Luis A Pérez de Llano, Alberto Fernández-Villar, Dolors Carnicer-Pont, Bernardino Alcázar-Navarrete, Arturo García, Aurelio Morales, María Lobo, Marcos Maroto, Eloy Ferreras, Cecilia Soriano, Carlos Del Rio-Bermudez, Lorena Vega-Piris, Xavier Basagaña, Josep Muncunill, Borja G Cosio, Sara Lumbreras, Carlos Catalina, José María Alzaga, David Gómez Quilón, Carlos Alberto Valdivia, Celia de Lara, Julio Ancochea. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 21.09.2020.

Références

Lancet. 2020 May 2;395(10234):1418-1420
pubmed: 32305073
Minerva Med. 2020 Jun 02;:
pubmed: 32491297
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Gac Sanit. 2020 May - Jun;34(3):217-219
pubmed: 32265049
Gac Sanit. 2018 Nov - Dec;32(6):563-566
pubmed: 28923337
Am J Epidemiol. 2010 Sep 15;172(6):737-9
pubmed: 20720100
J Med Internet Res. 2020 May 29;22(5):e17572
pubmed: 32348255
Swiss Med Wkly. 2020 May 17;150:w20282
pubmed: 32418194
Am J Pharm Educ. 2008 Apr 15;72(2):43
pubmed: 18483608
Nat Rev Microbiol. 2013 Jan;11(1):8
pubmed: 23202526
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
JMIR Public Health Surveill. 2020 May 4;6(2):e19106
pubmed: 32339998
Epidemiology. 2019 Jul;30(4):509-516
pubmed: 31033690
Eur J Epidemiol. 2020 Apr;35(4):321-324
pubmed: 32335765
BMJ. 2020 Jun 24;369:m2529
pubmed: 32580991
J Med Internet Res. 2020 Jun 16;22(6):e19284
pubmed: 32501804
Lancet. 2020 Jun 6;395(10239):1750
pubmed: 32505244
Gac Sanit. 2020 Apr 27;:
pubmed: 32417117
JMIR Public Health Surveill. 2020 Jun 1;6(2):e19033
pubmed: 32406855
N Engl J Med. 2020 Feb 20;382(8):692-694
pubmed: 31978293
JMIR Mhealth Uhealth. 2019 Apr 11;7(4):e11500
pubmed: 30973342
Ann Intern Med. 2020 Aug 18;173(4):297-299
pubmed: 32379854
JMIR Public Health Surveill. 2020 Apr 14;6(2):e18668
pubmed: 32250958

Auteurs

Joan B Soriano (JB)

Hospital Universitario La Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Esteve Fernández (E)

Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Unidad de Control del Tabaco, Centro Colaborador de la OMS para el Control del Tabaco, Institut Català d'Oncologia-ICO, Hospitalet de Llobregat, Barcelona, Spain.
Grupo de Control y Prevención del Cáncer, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Departamento de Ciencias Clínicas, Facultad de Medicina, Universitat de Barcelona, Hospitalet de Llobregat, Barcelona, Spain.

Álvaro de Astorza (Á)

Servicio de Neumología, Hospital de Can Misses, Ibiza, Spain.

Luis A Pérez de Llano (LA)

Servicio de Neumología, Hospital Lucus Augusti, Lugo, Spain.

Alberto Fernández-Villar (A)

Servicio de Neumología, Hospital Álvaro Cunqueiro, Vigo, Spain.

Dolors Carnicer-Pont (D)

Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Unidad de Control del Tabaco, Centro Colaborador de la OMS para el Control del Tabaco, Institut Català d'Oncologia-ICO, Hospitalet de Llobregat, Barcelona, Spain.
Grupo de Control y Prevención del Cáncer, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Departamento de Ciencias Clínicas, Facultad de Medicina, Universitat de Barcelona, Hospitalet de Llobregat, Barcelona, Spain.

Bernardino Alcázar-Navarrete (B)

Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Servicio de Neumología, Hospital de Alta Resolución de Loja, Loja, Spain.

Arturo García (A)

Fundación Teófilo Hernando, Madrid, Spain.

Aurelio Morales (A)

Fundación Teófilo Hernando, Madrid, Spain.

María Lobo (M)

Fundación Teófilo Hernando, Madrid, Spain.

Marcos Maroto (M)

Fundación Teófilo Hernando, Madrid, Spain.

Eloy Ferreras (E)

Fundación Teófilo Hernando, Madrid, Spain.

Cecilia Soriano (C)

CIMNE - International Center for Numerical Methods in Engineering, Barcelona, Spain.

Lorena Vega-Piris (L)

Unidad de Metodología, IIS del Hospital Universitario La Princesa, Madrid, Spain.

Xavier Basagaña (X)

ISGlobal, Universitat Pompeu Fabra, Barcelona, Spain.

Borja G Cosio (BG)

Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
IdISBa, Palma, Spain.
Servicio de Neumología, Hospital Universitari Son Espases, Palma, Spain.

Sara Lumbreras (S)

Institute for Research in Technology, Universidad Pontificia Comillas, Madrid, Spain.

Carlos Catalina (C)

ASELCIS Consulting, Madrid, Spain.

José María Alzaga (JM)

ASELCIS Consulting, Madrid, Spain.

David Gómez Quilón (D)

ASELCIS Consulting, Madrid, Spain.

Celia de Lara (C)

ASELCIS Consulting, Madrid, Spain.

Julio Ancochea (J)

Hospital Universitario La Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH